Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers.

about

Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers.

Item

http://www.wikidata.org/entity/Q50531788

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Reversibility of peripheral bl ...... ibitor, in healthy volunteers.

@en

Reversibility of peripheral bl ...... ibitor, in healthy volunteers.

@nl

type

Item

label

Reversibility of peripheral bl ...... ibitor, in healthy volunteers.

@en

Reversibility of peripheral bl ...... ibitor, in healthy volunteers.

@nl

prefLabel

Reversibility of peripheral bl ...... ibitor, in healthy volunteers.

@en

Reversibility of peripheral bl ...... ibitor, in healthy volunteers.

@nl

P1476

Reversibility of peripheral bl ...... ibitor, in healthy volunteers.

@en

P2093

Anasuya Hazra

http://www.w3.org/2001/XMLSchema#string

Ann Wouters

http://www.w3.org/2001/XMLSchema#string

Christopher F Mojcik

http://www.w3.org/2001/XMLSchema#string

Constance Hammond

http://www.w3.org/2001/XMLSchema#string

Jack F Bukowski

http://www.w3.org/2001/XMLSchema#string

James D Clark

http://www.w3.org/2001/XMLSchema#string

Janet S Staats

http://www.w3.org/2001/XMLSchema#string

Jennifer A Hodge

http://www.w3.org/2001/XMLSchema#string

John Cheng

http://www.w3.org/2001/XMLSchema#string

Kent J Weinhold

http://www.w3.org/2001/XMLSchema#string

P2860

The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis

Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses

Fate of lymphocytes after withdrawal of tofacitinib treatment

Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis.

Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).

Standardizing immunophenotyping for the Human Immunology Project.

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study.

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo.

Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study.

P304

10-20

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CLIM.2018.03.002

http://www.w3.org/2001/XMLSchema#string

P478

191

http://www.w3.org/2001/XMLSchema#string

P577

2018-03-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29518577

http://www.w3.org/2001/XMLSchema#string

P932

6036921

http://www.w3.org/2001/XMLSchema#string